These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 21128258

  • 1. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
    Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D.
    Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
    [Abstract] [Full Text] [Related]

  • 2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [Abstract] [Full Text] [Related]

  • 4. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
    Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y.
    Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
    [Abstract] [Full Text] [Related]

  • 5. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.
    N Engl J Med; 2005 Sep 15; 353(11):1114-23. PubMed ID: 16162882
    [Abstract] [Full Text] [Related]

  • 6. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH, Paediatric Rheumatology INternational Trials Organization, Pediatric Rheumatology Collaborative Study Group.
    Lancet; 2008 Aug 02; 372(9636):383-91. PubMed ID: 18632147
    [Abstract] [Full Text] [Related]

  • 7. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.
    J Rheumatol; 2012 Aug 02; 39(8):1546-54. PubMed ID: 22798265
    [Abstract] [Full Text] [Related]

  • 8. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
    Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW.
    Arthritis Rheum; 2005 Aug 02; 52(8):2263-71. PubMed ID: 16052582
    [Abstract] [Full Text] [Related]

  • 9. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
    Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE, Birbara C, Russell AS.
    J Rheumatol; 2006 Apr 02; 33(4):681-9. PubMed ID: 16568505
    [Abstract] [Full Text] [Related]

  • 10. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep 02; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 11. New therapies and new goals for psoriatic arthritis.
    Veale DJ.
    Arthritis Rheum; 2011 Apr 02; 63(4):874-6. PubMed ID: 21128255
    [No Abstract] [Full Text] [Related]

  • 12. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
    Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC.
    Ann Rheum Dis; 2007 Feb 02; 66(2):228-34. PubMed ID: 16935912
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2010 Jun 02; 62(6):1792-802. PubMed ID: 20191582
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    Arthritis Rheum; 2005 Oct 02; 52(10):3279-89. PubMed ID: 16200601
    [Abstract] [Full Text] [Related]

  • 15. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
    Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E.
    Arthritis Rheum; 2006 Sep 02; 54(9):2807-16. PubMed ID: 16947384
    [Abstract] [Full Text] [Related]

  • 16. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.
    Arthritis Rheum; 2012 Oct 02; 64(10):3156-67. PubMed ID: 22806399
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH, M02-570 Study Group.
    J Rheumatol; 2007 May 02; 34(5):1040-50. PubMed ID: 17444593
    [Abstract] [Full Text] [Related]

  • 18. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A, Pham DQ.
    Clin Ther; 2006 Nov 02; 28(11):1764-78. PubMed ID: 17212998
    [Abstract] [Full Text] [Related]

  • 19. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
    Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.
    J Rheumatol; 2010 Jun 02; 37(6):1221-7. PubMed ID: 20395648
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
    Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.
    Ann Rheum Dis; 2017 Sep 02; 76(9):1550-1558. PubMed ID: 28473423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.